These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8239597)

  • 1. Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.
    Van der Auwera P; Duchateau V; Lambert C; Husson M; Kinzig M; Sörgel F
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1860-8. PubMed ID: 8239597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
    Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.
    Fournier JL; Ramisse F; Jacolot AC; Szatanik M; Petitjean OJ; Alonso JM; Scavizzi MR
    Antimicrob Agents Chemother; 1996 Feb; 40(2):325-30. PubMed ID: 8834874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
    Anuradha K; Sailaja VV; Umabala P; Satheesh T; Lakshmi V
    Indian J Med Microbiol; 2007 Jul; 25(3):203-8. PubMed ID: 17901635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
    Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M; Yang Y; Livermore DM
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antibacterial activities of ticarcillin alone and ticarcillin plus clavulanic acid against beta-lactamase producing and non-producing microorganisms.
    Hsueh PR; Chang SC; Chen YC; Hsu LY; Luh KT; Hsieh WC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1992 Aug; 25(3):149-59. PubMed ID: 1342000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity.
    Muñoz Bellido JL; Muñoz Criado S; García García I; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; García-Rodríguez JA
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2612-5. PubMed ID: 9420028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae.
    Kempers J; MacLaren DM
    J Antimicrob Chemother; 1990 Oct; 26(4):598-9. PubMed ID: 2174855
    [No Abstract]   [Full Text] [Related]  

  • 19. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
    Knapp CC; Sierra-Madero J; Washington JA
    Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other beta-lactams.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1984 Feb; 13(2):121-8. PubMed ID: 6323375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.